No Data
Express News | Lepu Medical Technology: Transcatheter implantable aortic valve system has obtained NMPA registration approval.
Lepu Biopharma Renews Procurement Contract With Controlling Shareholder
Lepu Biotechnology-B(02157.HK) and Lepu Medical Technology have signed a CDMO service framework agreement.
Gelonghui November 26th丨Lepu Biopharmaceutical-B (02157.HK) announced that on November 26, 2024, the company entered into a CDMO service framework agreement with lepu medical technology, under which the company and/or its subsidiaries agree to provide CDMO technical services and related supporting equipment to lepu medical technology and/or its subsidiaries.
Hong Kong stock market anomaly | Xintai Medical (02291) surged more than 30% in the morning session, recently renewed a framework agreement with Lepu Medical Technology, and the trading volume may increase year by year in the next three years.
Heartai Medical (02291) rose over 30% in early trading, as of the time of writing, up 30.92%, priced at HKD 22.1, with a trading volume of HKD 19.5613 million.
Express News | lepu medical technology: Subsidiaries MWN105 injection, MWN109 injection obtained the drug clinical trial approval notice.
Lepu Medical Technology (300003): The impact of channel adjustments in the pharmaceutical sector is expected to come to an end. Innovative medical devices continue to maintain high growth.
Investment Highlights: The company released the third quarter report for 2024. In Q1-Q3 2024, the company achieved revenue of 4.785 billion yuan (-23.55% year-on-year), net income attributable to the parent company of 0.803 billion yuan (-40.70% year-on-year), net of non-recurring gains and losses.
No Data
